Possible risk factors for the development of sodium-glucose co-transporter 2 inhibitor-associated diabetic ketoacidosis in type 2 diabetes

British Journal of Diabetes and Vascular Disease

Volumn 16, Issue 2, 2016, Pages 78-81

  Kate, West ^a   Webb, Lucy Anne ^a   Matthew, Fenech ^b   Ketan, Dhatariya ^a,b  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Diabetic ketoacidosis; SGLT 2 inhibitors

Indexed keywords

DAPAGLIFLOZIN; EXENDIN 4; GLICLAZIDE; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL (TOPIC); DIABETIC KETOACIDOSIS; DIET THERAPY; DISEASE DURATION; DRUG DOSE INCREASE; DRUG INDICATION; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OFF LABEL DRUG USE; PANCREAS ISLET BETA CELL; RISK FACTOR;

EID: 84974725278     PISSN: 14746514     EISSN: 17534305     Source Type: Journal    
DOI: 10.15277/bjd.2016.079     Document Type: Article

References (20)

1. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. 2015. [Last accessed 18 December 2015]
2. European Medicines Agency. Review of diabetes medicines called SGLT2 inhibitors started. http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/SGLT2-inhibitors-20/Procedure-started/WC500187926.pdf. 2015. [Last accessed 18 December 2015]
3. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687-93. http://dx.doi.org/10.2337/dc15-0843
4. Taylor SI, Blau JE, Rother KI. Perspective: SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015;100:2849-52. http://dx.doi.org/10.1210/jc.2015-1884
5. Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015;38:1680-6. http://dx.doi.org/10.2337/dc15-1251
6. Dhatariya K. Comment on Erondu N et al - Does this data significantly underestimate the prevalence of SGLT-2 associated DKA? Diabetes Care 2016;39(1):e18.
7. Hine J, Paterson H, Abrol E, et al. SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabetes Endocrinol 2015;3:503-04. http://dx.doi.org/10.1016/S2213-8587(15)00204-1
8. Burr K, Nguyen A-T, Rasouli N. A case report of ketoacidosis associated with canagliflozin (Invokana). http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2015.DGM.5.SAT-595. 2015. [Last accessed 18 December 2015]
9. Hayami T, Kato Y, Kamiya H, et al. Case of ketoacidosis by a sodiumglucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig 2015;6:587-90. http://dx.doi.org/10.1111/jdi.12330
10. Dhatariya K, Savage M, Kelly T, et al. Joint British Diabetes Societies Inpatient Care Group. The management of diabetic ketoacidosis in adults. Second edition. Update: September 2013. http://www.diabetologistsabcd.org.uk/JBDS/JBDS.htm. 2013 [Last accessed 18 December 2015]
11. Clar C, Gill JA, Court R, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012; 2. http://dx.doi.org/10.1136/bmjopen-2012-001007
12. Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 2014;727:66-74. http://dx.doi.org/10.1016/j.ejphar.2014.01.040
13. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodiumglucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508. http://dx.doi.org/10.1172/JCI72227
14. Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 2014;13:65. http://dx.doi.org/10.1186/1475-2840-13-65
15. Nadel E. Metabolism and nutition. In: Medical Physiology. Boron W, Boulpaep E, eds. Philadelphia: Saunders/Elsevier, 2015, p.1230.
16. Bonner C, Kerr-conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nature Med 2015;21:512-17. http://dx.doi.org/10.1038/nm.3828
17. Holman RR. Assessing the potential for a-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998;40:S21-5. http://dx.doi.org/10.1016/S0168-8227(98)00038-2
18. Merovci A, Mari A, Solis C, et al. Dapagliflozin lowers plasma glucose concentration and improves β-cell function. J Clin Endocrinol Metab 2015;100:1927-32. http://dx.doi.org/10.1210/jc.2014-3472
19. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9. http://dx.doi.org/10.2337/dc14-2441
20. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28. http://dx.doi.org/10.1056/NEJMoa1504720